Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Single-Arm Study of Coversin in Adult aHUS Subjects
2017-000064-15Phase 2Terminated
- Sponsor
- Akari Therapeutics
- Start
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nomacopan in atypical hemolytic uremic syndrome (aHUS) and hemolytic uremic syndrome (HUS), sponsored by Akari Therapeutics. Primary endpoint: Normal platelet count at day 180. Started Jun 2017; status: terminated.
02
Drugs
nomacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)hemolytic uremic syndrome (HUS)
Beyond the preview
Go deeper on 2017-000064-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000064-15.